Recent advancement in biomarkers to predict the clinical outcome for colorectal cancer patients
Ichikawa, W.
Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl. 3: 220-225
2011
ISSN/ISBN: 0047-1852 PMID: 22213961 Document Number: 652562
Document emailed within 1 workday
Related Documents
Suzuki, H.; Yamamura, T. 1990: DNA ploidy of tumor cells and clinical outcome of colorectal cancer patients Journal of Clinical Gastroenterology 12(5): 603-604Techawathanawanna, S.; Nimmannit, A.; Akewanlop, C. 2012: Clinical characteristics and disease outcome of UICC stages I-IIi colorectal cancer patients at Siriraj Hospital Journal of the Medical Association of Thailand 95(Suppl 2): S189-S198
Ahnen, D.J.; Feigl, P.; Quan, G.; Fenoglio-Preiser, C.; Lovato, L.C.; Bunn, P.A.; Stemmerman, G.; Wells, J.D.; Macdonald, J.S.; Meyskens, F.L. 1998: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study Cancer Research 58(6): 1149-1158
Feola, M. 2016: The prognostic value of different biomarkers in predicting clinical outcome in discharged heart failure patients Minerva Cardioangiologica 64(2): 145-146
Bai, Y.-q.; Liu, X.-j.; Wang, Y.; Ge, F.-j.; Zhao, C.-h.; Fu, Y.-l.; Lin, L.; Xu, J.-m. 2013: Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer Zhonghua Zhong Liu Za Zhi 35(9): 666-671
Julián-Jiménez, A.; Candel, F.J.; González-Del Castillo, J. 2017: Usefulness of biomarkers to predict bacteraemia in patients with infection in the emergency department Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad Espanola de Quimioterapia 30(4): 245-256
Berglund, A.; Edler, D.; Molin, D.; Nordlinder, H.; Graf, W.; Glimelius, B. 2002: Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma Anticancer Research 22(6b): 3653-3659
Bosman, F.T. 2009: Predictive biomarkers in colorectal cancer Revue Medicale Suisse 5(211): 1513-1518
Jia, X.; Han, C. 2000: Biomarkers in the studies on chemoprevention of colorectal cancer Wei Sheng Yan Jiu 29(2): 109-111
Honjou, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Ishiguro, T.; Kuwabara, K.; Ohsawa, T.; Kumamoto, K.; Tsuji, Y.; Haga, N.; Iwama, T.; Ishida, H. 2011: The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(12): 2216-2219
Lech, G.; Slotwinski, R.; Krasnodebski, I.W. 2014: The role of tumor markers and biomarkers in colorectal cancer Neoplasma 61(1): 1-8
Katsuki, S.; Oui, M.; Takayama, T.; Takahashi, Y.; Shuichi, N.; Niitsu, Y. 1998: Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer Nihon Geka Gakkai Zasshi 99(6): 379-384
Chang, Y.-Y.; Lin, J.-K.; Lin, T.-C.; Chen, W.-S.; Jeng, K.-J.; Yang, S.-H.; Wang, H.-S.; Lan, Y.-T.; Lin, C.-C.; Liang, W.-Y.; Chang, S.-C. 2014: Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer Hepato-Gastroenterology 61(135): 1946-1953
Tohmé, C.; Labaki, M.; Hajj, G.; Abboud, B.; Noun, R.; Sarkis, R. 2008: Colorectal cancer in young patients: presentation, clinicopathological characteristics and outcome Le Journal Medical Libanais. Lebanese Medical Journal 56(4): 208-214
Kingston, R.D.; Walsh, S.H.; Jeacock, J. 1993: Physical status is the principal determinant of outcome after emergency admission of patients with colorectal cancer Annals of the Royal College of Surgeons of England 75(5): 335-338
Kuroiwa, K. 2016: Efficacy of nomograms based on Japanese patients which predict clinical outcomes of prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 183-187
Tural, D.; Selcukbiricik, F.; Erdamar, S.; Ozkurt, C.Unlu.; Yanmaz, T.; Mandel, N.Molinas.; Serdengeçti, Süheyla. 2013: Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab Hepato-Gastroenterology 60(125): 1035-1040
Reynolds, P.M.; Grimsley, G.; Dawkins, R.L.; Byrne, M.J.; Zilko, P.J. 1980: Immunological status may predict clinical outcome in BCG treated melanoma Australian and New Zealand Journal of Medicine 10(1): 39-43
Yonemura, Y.; Canbay, E.; Sako, S.; Wakama, S.; Ishibashi, H.; Hirano, M.; Mizumoto, A.; Takao, N.; Ichinose, M.; Noguchi, K.; Motoi, S.; Liu, Y.; Li, Y.; Taniguchi, K. 2017: Comprehensive Treatment Using Cytoreductive Surgery Combined with Perioperative Chemotherapy Improved Outcome of Colorectal Cancer Patients with Metachronous Peritoneal Metastasis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(12): 1939-1942
Jessup, J.M.; Giavazzi, R.; Campbell, D.; Cleary, K.R.; Morikawa, K.; Hostetter, R.; Atkinson, E.N.; Fidler, I.J. 1989: Metastatic potential of human colorectal carcinomas implanted into nude mice: prediction of clinical outcome in patients operated upon for cure Cancer Research 49(24 Part 1): 6906-6910